Literature DB >> 2821105

Reovirus type 3 infection in patients with primary biliary cirrhosis and primary sclerosing cholangitis.

G Y Minuk1, N Rascanin, R W Paul, P W Lee, K Buchan, J K Kelly.   

Abstract

Reovirus type 3 (Reo-3) infection has recently been implicated in the pathogenesis of certain idiopathic, cholestatic liver diseases of newborns. In the present study, antibody titres to Reo-3 virus (anti-Reo-3) were determined in sera from 43 adults with idiopathic cholestatic liver disease, including 34 patients with primary biliary cirrhosis (PBC) and 9 patients with primary sclerosing cholangitis (PSC). Seventy-four adults with various other causes of chronic liver disease and 16 healthy volunteers served as controls. Geometric mean titres of anti-Reo-3 were significantly higher in PBC and PSC sera than chronic liver disease and healthy controls (P less than 0.005). Mean antibody titres for all patient groups, however, were within the 95% confidence limits for normals. Seven of 34 (21%) PBC patients and 3/9 (33%) PSC patients had elevated titres of anti-Reo-3, as compared to only 4/74 (5%) chronic liver disease (P less than 0.05) and 0/16 (0%) healthy control subjects (P less than 0.05) (Fisher's Exact Test). Antibody titres to five other common viruses were normal in patients with high anti-Reo-3 titres when compared to age- and sex-matched controls with liver disease. Immunoperoxidase staining for Reo-3 viral markers and cultures of liver biopsy material for Reo-3 virus were negative in both patients and controls. The results of this study indicate that, although patients with PBC and PSC have higher anti-Reo-3 antibody titres than patients with other forms of chronic liver disease or healthy volunteers, only a minority of these patients have titres that exceed the 95% confidence limits for normals.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2821105     DOI: 10.1016/s0168-8278(87)80054-5

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  15 in total

1.  Reovirus as a novel oncolytic agent.

Authors:  K L Norman; P W Lee
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

2.  A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report.

Authors:  E Anders Kolb; Valerie Sampson; Deborah Stabley; Alexa Walter; Katia Sol-Church; Timothy Cripe; Pooja Hingorani; Charlotte Hsieh Ahern; Brenda J Weigel; James Zwiebel; Susan M Blaney
Journal:  Pediatr Blood Cancer       Date:  2015-02-27       Impact factor: 3.167

Review 3.  Aetiology and natural history of primary sclerosing cholangitis--a decade of progress?

Authors:  R W Chapman
Journal:  Gut       Date:  1991-12       Impact factor: 23.059

Review 4.  Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis.

Authors:  K M Das
Journal:  Dig Dis Sci       Date:  1999-01       Impact factor: 3.199

Review 5.  The immunology of primary sclerosing cholangitis.

Authors:  R W Chapman
Journal:  Springer Semin Immunopathol       Date:  1990

Review 6.  Primary sclerosing cholangitis.

Authors:  Y Ueno; N F LaRusso
Journal:  J Gastroenterol       Date:  1994-08       Impact factor: 7.527

7.  Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma.

Authors:  Evanthia Galanis; Svetomir N Markovic; Vera J Suman; Gerard J Nuovo; Richard G Vile; Timothy J Kottke; Wendy K Nevala; Michael A Thompson; Jean E Lewis; Kandelaria M Rumilla; Victoria Roulstone; Kevin Harrington; Gerald P Linette; William J Maples; Matt Coffey; James Zwiebel; Kari Kendra
Journal:  Mol Ther       Date:  2012-08-07       Impact factor: 11.454

8.  Synergism between hepatic injuries and a nonhepatotropic reovirus in mice. Enhanced hepatic infection and death.

Authors:  D A Piccoli; C L Witzleben; C J Guico; A Morrison; D H Rubin
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

9.  Utilization of sialic acid as a coreceptor is required for reovirus-induced biliary disease.

Authors:  Erik S Barton; Bryan E Youree; Daniel H Ebert; J Craig Forrest; Jodi L Connolly; Tibor Valyi-Nagy; Kay Washington; J Denise Wetzel; Terence S Dermody
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

10.  Differential serum levels of eosinophilic eotaxins in primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis.

Authors:  Abdolamir Landi; Tobias J Weismuller; Tim O Lankisch; Deanna M Santer; D Lorne J Tyrrell; Michael P Manns; Michael Houghton
Journal:  J Interferon Cytokine Res       Date:  2013-10-29       Impact factor: 2.607

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.